AMF REGULATED INFORMATION
Montrouge, France, July 27, 2022
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
As of June 30, 2022, the following assets appeared on the liquidity account:
- 106,287 DBV Technologies shares;
- € 430,854.35.
Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:
- 41,159 DBV Technologies ordinary shares;
- € 432,367.25.
Number of transactions executed during the first half-year of 2022:
- Purchase: 706
- Sale: 869
Over the same period, the volumes traded represented:
- 345,064 DBV Technologies ordinary shares purchased for €1,056,560.18
- 392,408 DBV Technologies ordinary shares sold for €1,311,871.05
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Viaskin and EPIT are trademarks of DBV Technologies.